Search results for "ACUTE HEART FAILURE"

showing 10 items of 25 documents

Acute decompensated heart failure: Decision pathways for older people

2015

Introduction: Acute decompensated heart failure (ADHF) is a common condition in older people, but little research has been conducted on the appropriate decision pathways for this population. The aim of this review was to explore ADHF management in older people, paying particular attention to the comprehensive geriatric assessment (CGA). Material and methods: A search was run in the PubMed literature database, combining the term "acute heart failure" with "management", "geriatric" "multidisciplinary", "co-management", "co-care", "approach", and "comprehensive geriatric assessment", from the databases inception to 1st January 2015. A manual check was also conducted on the reference lists in t…

medicine.medical_specialtyeducation.field_of_studyAcute decompensated heart failureacute heart failurebusiness.industryMortality ratePopulationEmergency departmentcomprehensive geriatric assessmentmedicine.diseaseMultidisciplinary approachHeart failureIntensive caremedicineGeriatrics and GerontologyDisease management (health)Intensive care medicinebusinesseducationGerontologyEuropean Geriatric Medicine
researchProduct

Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure

2020

AIMS: Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and is related with worse outcomes. Insulin treatment is associated with sodium and water retention, weight gain, and hypoglycaemia-all pathophysiological mechanisms related to HF decompensation. This study aimed to evaluate the association between insulin treatment and the risk of 1year readmission for HF in patients discharged for acute HF.; METHODS AND RESULTS: We prospectively included 2895 consecutive patients discharged after an episode of acute HF in a single tertiary hospital. Multivariable Cox regression, adapted for competing events, was used to assess the association between insulin treatment and …

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusOriginal Research ArticlesType 2 diabetes mellitusmedicineDiseases of the circulatory (Cardiovascular) systemDecompensation030212 general & internal medicineOriginal Research ArticleEjection fractionbusiness.industryProportional hazards modelInsulinHazard ratioType 2 Diabetes MellitusAcute heart failureHospital readmissionmedicine.diseaseHeart failureRC666-701Insulin therapyCardiology and Cardiovascular Medicinebusiness
researchProduct

Plasma neutrophil gelatinase-associated lipocalin and long-term mortality in patients with acute heart failure and normal renal function

2015

Neutrophil gelatinase-associated lipocalin (NGAL) has emerged as a renal tubular marker for early renal dysfunction [1]. Recent studies highlighted its role in predicting acute kidney injury (AKI) and clinical outcomes in a wide range of cardiovascular diseases [2], [3], [4] and [5]. However, in heart failure (HF), conflicting results have been reported [4], [5], [6] and [7] and some ambiguities still prevail about the prognostic utility of NGAL beyond standard prognosticators and traditional renal biomarkers. We aimed to evaluate the independent ability of serum NGAL for predicting long-term mortality in patients admitted for acute HF (AHF). We prospectively enrolled 206 patients consecuti…

Malemedicine.medical_specialtyRenal function030204 cardiovascular system & hematologyKidneyKidney Function TestsGastroenterology03 medical and health sciencesNormal renal function0302 clinical medicineText miningLipocalin-2Risk FactorsInternal medicinemedicineHumansIn patient030212 general & internal medicineProspective StudiesMortalityProspective cohort studyAgedAged 80 and overHeart Failurebusiness.industryPlasma neutrophilAcute heart failureMiddle Agedmedicine.diseasePrognosisNeutrophil gelatinase-associated lipocalinHeart failureRenal physiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersRenal function
researchProduct

Prognostic value of the interaction between galectin-3 and antigen carbohydrate 125 in acute heart failure

2015

AIM:Galectin-3 (Gal-3) and carbohydrate antigen 125 (CA125) have emerged as robust prognostic biomarkers in heart failure. Experimental data have also suggested a potential molecular interaction between CA125 and Gal-3; however, the biological and clinical relevance of this interaction is still uncertain. We sought to evaluate, in patients admitted for acute heart failure, the association between plasma Gal-3 with all-cause mortality and the risk for rehospitalizations among high and low levels of CA125. METHODS AND RESULTS: We included 264 consecutive patients admitted for acute heart failure to the Cardiology Department in a third-level center. Both biomarkers were measured on admission. …

Maleendocrine system diseasesGalectin 3lcsh:MedicineRisk FactorsBlood plasmaANTIGEN CARBOHYDRATE 125lcsh:ScienceAged 80 and overMultidisciplinaryca125Mortality rateBlood Proteins//purl.org/becyt/ford/3.1 [https]Middle AgedPrognosisMedicina BásicaGalectin-3Female//purl.org/becyt/ford/3 [https]Research Articlemedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDcontributesGalectinsInmunologíaPatient ReadmissionAntigenInternal medicinemedicineHumanssurfaceClinical significanceIn patientIntensive care medicineAgedProportional Hazards ModelsHeart FailureGALECTIN-3business.industryProportional hazards modellcsh:Rassociationmedicine.diseaseACUTE HEART FAILUREstatin therapyinflammationCA-125 AntigenHeart failurecellslcsh:QbusinessBiomarkersFollow-Up Studies
researchProduct

Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF

2020

Aims: \ud This retrospective analysis sought to identify markers that might distinguish between acute heart failure (HF) and worsening HF in chronic outpatients.\ud \ud Methods and Results: \ud The BIOSTAT‐CHF index cohort included 2516 patients with new or worsening HF symptoms: 1694 enrolled as inpatients (acute HF) and 822 as outpatients (worsening HF in chronic outpatients). A validation cohort included 935 inpatients and 803 outpatients. Multivariable models were developed in the index cohort using clinical characteristics, routine laboratory values, and proteomics data to examine which factors predict adverse outcomes in both conditions and to determine which factors differ between ac…

medicine.medical_specialtyAdverse outcomesacute heart failure treatment030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemacute heart failure diagnosisInternal medicineOutpatientsDiagnosismedicineRetrospective analysisHumansAcute heart failure; acute heart failure diagnosis; acute heart failure treatmentRetrospective StudiesHeart Failurebusiness.industryTreatment developmentRoutine laboratoryAcute heart failurePrognosismedicine.diseaseR1[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHospitalizationTreatmentHeart failureChronic DiseaseCohortBiomarker (medicine)Cardiology and Cardiovascular MedicinebusinessCarbohydrate antigen
researchProduct

Factors associated with plasma antigen carbohydrate 125 and amino-terminal pro-B-type natriuretic peptide concentrations in acute heart failure

2020

Background: Plasma amino-terminal pro-B-type natriuretic peptide and antigen carbohydrate 125 levels are positively associated with a higher risk of adverse clinical outcomes in acute heart failure. As a proxy of congestion, antigen carbohydrate 125 has also been proposed as a right-sided heart failure marker. Thus, we aimed to determine in this population the main factors – including echocardiographic right-sided heart failure parameters – associated with antigen carbohydrate 125 and amino-terminal pro-B-type natriuretic peptide. Methods and results: We prospectively included 2949 patients admitted with acute heart failure. Amino-terminal pro-B-type natriuretic peptide and antigen carbohy…

Malemedicine.medical_specialtymedicine.drug_classacute heart failureAmino terminalCa 125 antigen030204 cardiovascular system & hematologyCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineAntigenInternal medicineNatriuretic Peptide BrainNatriuretic peptidemedicineHumans030212 general & internal medicineProspective Studiesright-sided heart failureProtein PrecursorsAgedHeart Failurebusiness.industryGeneral MedicineCarbohydratemedicine.diseasePrognosisPeptide FragmentsEndocrinologyEchocardiographyNT-proBNPHeart failureCA-125 AntigenAcute DiseaseDisease ProgressionFemaleAntigen carbohydrate 125Cardiology and Cardiovascular MedicinebusinessRight-sided heart failureBiomarkersFollow-Up Studies
researchProduct

Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute hea…

2017

Aim: Baseline values of N-terminal pro B-type natriuretic peptide (NT-proBNP) and carbohydrate antigen 125 (CA125) predict all-cause mortality in acute heart failure (AHF). However, there is limited information about the added prognostic benefit of using longitudinal values, and how this predictive ability is modified when modelling together. The aim of this study was to determine the mutually-adjusted association between the longitudinal trajectories of NT-proBNP and CA125 with all-cause mortality after an episode of AHF. Methods and results: We included 946 consecutive patients discharged for AHF. NT-proBNP and CA125 were measured at each physician-patient encounter (median (interquartile…

Malemedicine.medical_specialtyLongitudinal studyTime Factorsacute heart failuremedicine.drug_class030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineRisk Assessment03 medical and health sciences0302 clinical medicineInterquartile rangeRisk FactorsInternal medicineCause of DeathNatriuretic Peptide BrainmedicineNatriuretic peptideHumans030212 general & internal medicineMortalitycarbohydrate antigen 125Survival rateCause of deathAgedRetrospective StudiesHeart Failurebusiness.industrylongitudinal studyMembrane ProteinsRetrospective cohort studyGeneral MedicineBrain natriuretic peptidemedicine.diseasePrognosisPeptide FragmentsSurvival RateEndocrinologyB-type natriuretic peptideSpainHeart failureCA-125 AntigenAcute DiseaseCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesEuropean heart journal. Acute cardiovascular care
researchProduct

Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study

2021

AIMS: Although acute heart failure (AHF) with volume overload is treated with loop diuretics, their dosing and type of administration are mainly based upon expert opinion. A recent position paper from the Heart Failure Association (HFA) proposed a step-wise pharmacologic diuretic strategy to increase the diuretic response and to achieve rapid decongestion. However, no study has evaluated this protocol prospectively. METHODS AND RESULTS: The Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure (ENACT-HF) study is an international, multicentre, non-randomized, open-label, pragmatic study in AHF patients on chronic loop diuretic therapy, admitted to the hospital for intravenous …

medicine.drug_classmedicine.medical_treatmentStudy DesignsDecongestionVolume overloadDiuresisNatriuresisSodium Potassium Chloride Symporter InhibitorsFurosemideAcute heart failure; Diuretics; Urinary sodium; Decongestion; ProtocolmedicineClinical endpointProtocolHumansDiseases of the circulatory (Cardiovascular) systemInfusions IntravenousDiureticsHeart FailureUrinary sodiumStudy Designbusiness.industryFurosemideAcute heart failureLoop diureticmedicine.diseaseAnesthesiaHeart failureRC666-701DiureticCardiology and Cardiovascular Medicinebusinessmedicine.drugESC Heart Failure
researchProduct

Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish…

2020

Levosimendan is a new inodilator which involves 3 main mechanisms: increases the calcium sensitivity of cardiomyocytes, acts as a vasodilator due to the opening of potassium channels, and has a cardioprotective effect. Levosimendan is mainly used in the treatment of acute decompensated heart failure (class IIb recommendation according to the European Society of Cardiology guidelines). However, numerous clinical trials indicate the validity of repeated infusions of levosimendan in patients with stable heart failure as a bridge therapy to heart transplantation, and in patients with accompanying right ventricular heart failure and pulmonary hypertension. Due to the complex mechanism of action,…

medicine.medical_specialtyCardiotonic AgentsAcute decompensated heart failureinotropic agentsacute heart failuremedicine.medical_treatment030204 cardiovascular system & hematologylevosimendan03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansinodilatorAdverse effectExpert TestimonySimendanHeart FailureHeart transplantationbusiness.industryHydrazonesLevosimendanmedicine.diseasePulmonary hypertensionCardiac surgeryPyridazinesClinical trialHeart failurechronic advanced systolic heart failureCardiologyPolandCardiology and Cardiovascular Medicinebusinessmedicine.drugKardiologia Polska
researchProduct

Decongestion discriminates risk for one-year mortality in patients with improving renal function in acute heart failure

2021

Aims Improving renal function (IRF) is paradoxically associated with worse outcomes in acute heart failure (AHF), but outcomes may differ based on response to decongestion. We explored if the relationship of IRF with mortality in hospitalized AHF patients differs based on successful decongestion.Methods and results We evaluated 760 AHF patients from AKINESIS for the relationship between IRF, change in B-type natriuretic peptide (BNP), and 1-year mortality. IRF was defined as a >= 20% increase in estimated glomerular filtration rate (eGFR) relative to admission. Adequate decongestion was defined as a >= 40% decrease in last measured BNP relative to admission. IRF occurred in 22% of pat…

InotropeMalemedicine.medical_specialtymedicine.drug_classRenal function030204 cardiovascular system & hematologyKidney03 medical and health sciences0302 clinical medicineKidney functionNatriuretic PeptideB&#8208Internal medicineNatriuretic Peptide BrainNatriuretic peptidemedicinetype natriuretic peptideHumansBlood urea nitrogenAgedHeart Failurebusiness.industryAcute heart failure; B-type natriuretic peptide; Congestion; Kidney function; Prognosis; Acute Disease; Aged; Biomarkers; Humans; Kidney; Male; Natriuretic Peptide Brain; Prognosis; Heart FailureHazard ratioBrainAcute heart failuremedicine.diseasePrognosisConfidence interval3. Good healthBlood pressureB-type natriuretic peptideHeart failureAcute DiseaseCardiologyCongestionCardiology and Cardiovascular MedicinebusinessBiomarkersEuropean Journal of Heart Failure
researchProduct